Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00272649 · ClinicalTrials.gov registry record · Phase 1
Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer
A Phase 1 study of Renal Cell Carcinoma, sponsored by Argos Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 10
- Study locations
NCT00272649 is a Phase 1 study of Renal Cell Carcinoma that has completed, run by Argos Therapeutics. The registered enrollment target is 22 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (91% lower). The trial reports 10 study locations across 10 states.
The verdict
NCT00272649, a Phase 1 study of Renal Cell Carcinoma, has completed, sponsored by Argos Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this trial is to examine the safety, feasibility, immunological response, and clinical antitumor activity of multiple administrations of dendritic cell Immunotherapeutic to patients with newly diagnosed with metastatic kidney cancer
Conditions Studied
Interventions
- BIOLOGICAL AGS-003
Study Locations (10)
California
- UCLA Kidney Cancer Program - Los Angeles
Colorado
- Univ. of Colorado Health Science Center - Division of Medical Oncology - Aurora
Georgia
- Emory University - Atlanta
Indiana
- The Indiana University Cancer Center/IUPUI - Indianapolis
Nevada
- Nevada Cancer Institute - Las Vegas
New York
- Roswell Park Cancer Institute - Buffalo
North Carolina
- Carolinas Medical Center/Blumenthal Cancer Center - Charlotte
Oregon
- Earle A. Chiles Research Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2006-01 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00272649
The ClinicalTrials.gov registry entry for NCT00272649 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (91% lower). The listed sponsor is Argos Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which AGS-003 is the first listed.
NCT00272649 reports 10 study locations spanning 10 distinct geographic areas - top geographies include California, Colorado, Georgia.
Frequently Asked Questions
What is clinical trial NCT00272649 about?
NCT00272649 is a clinical study titled "Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer". The purpose of this trial is to examine the safety, feasibility, immunological response, and clinical antitumor activity of multiple administrations of dendritic cell Immunotherapeutic to patients with newly diagnosed with metastatic kidney cancer
What is the current status of trial NCT00272649?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2006-01. Estimated completion is 2012-02.
What conditions does trial NCT00272649 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma.
What interventions are being tested in trial NCT00272649?
The interventions under investigation include: AGS-003 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00272649?
This trial is sponsored by Argos Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00272649 being conducted?
This trial has 10 study locations across California, Colorado, Georgia, Indiana, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
RECRUITING · Phase 1
-
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
-
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.